单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,然而在体外扩增过程中及回输后,调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。
英文原题:Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
在本研究中,我们根据临床级TIL生产方案,对未经治疗的肾细胞癌(RCC)患者的肿瘤样本(n = 58)、“快速扩增前”TIL(pre-REP TIL,n = 15)和“快速扩增”TIL(REP TIL,n = 25)进行了单细胞RNA(scRNA)+TCR测序(TCR sequencing)、TCR测序(TCR-seq)和流式细胞术分析。
未经标记:扩增的TIL(肿瘤浸润淋巴细胞)在过继性TIL治疗中的成功应用已有报道,但TIL扩增的效果、免疫表型、功能以及输注产品的T细胞受体(TCR) repertoire 相对于肿瘤微环境(TME)的关系尚不十分清楚。在本研究中,我们根据临床级TIL生产方案,采用单细胞RNA(scRNA)+TCR测序(TCR sequencing)、TCR测序(TCR-seq)和流式细胞术,分析了来自未经治疗肾细胞癌(RCC)患者的肿瘤样本(n = 58)、“快速扩增前”TIL(pre-REP TIL,n = 15)和“快速扩增”TIL(REP TIL,n = 25)。与pre-REP TIL和肿瘤T细胞相比,REP TIL中CD4+ T细胞的数量多于CD8+ T细胞,且CD4+和CD8+ T细胞区室中LAG-3表达增加、PD-1表达较低。REP方案优先扩增TME中CD4+表型(CD4、IL7R、KLRB1)的小克隆,表明肿瘤中最大的耗竭T细胞克隆在扩增方案中并未扩增。此外,通过从>1,000例scRNA+TCR-seq和TCR-seq RCC、健康及其他癌症样本队列中生成RCC相关TCR motif目录,我们对扩增方案中的RCC相关TCR进行了定量。与整个扩增过程中抗病毒TCR的剩余量较低不同,RCC相关TCR的数量在肿瘤和pre-REP TIL中较高,但在REP TIL中降低。我们的结果深入揭示了RCC TIL产品的来源、表型和TCR特异性,为更合理化的TIL生产铺平了道路。意义:TIL 是一组异质性免疫细胞,能够识别并攻击肿瘤,因此被用于多种临床试验。在本研究中,我们通过使用临床级方案扩增 TIL,探索了肾癌患者中的 TIL,并利用深入的实验和计算工具观察了它们的特征及识别肿瘤的能力。
UNLABELLED: The successful use of expanded tumor-infiltrating lymphocytes (TIL) in adoptive TIL therapies has been reported, but the effects of the TIL expansion, immunophenotype, function, and T cell receptor (TCR) repertoire of the infused products relative to the tumor microenvironment (TME) are not well understood. In this study, we analyzed the tumor samples ( n = 58) from treatment-na ve patients with renal cell carcinoma (RCC), "pre-rapidly expanded" TILs (pre-REP TIL, n = 15) and "rapidly expanded" TILs (REP TIL, n = 25) according to a clinical-grade TIL production protocol, with single-cell RNA (scRNA)+TCR -seq (TCR sequencing), TCR -sequencing (TCR -seq), and flow cytometry. REP TILs encompassed a greater abundance of CD4 + than CD8 + T cells, with increased LAG-3 and low PD-1 expressions in both CD4 + and CD8 + T cell compartments compared with the pre-REP TIL and tumor T cells. The REP protocol preferentially expanded small clones of the CD4 + phenotype ( CD4 , IL7R , KLRB1 ) in the TME, indicating that the largest exhausted T cell clones in the tumor do not expand during the expansion protocol. In addition, by generating a catalog of RCC-associated TCR motifs from >1,000 scRNA+TCR -seq and TCR -seq RCC, healthy and other cancer sample cohorts, we quantified the RCC-associated TCRs from the expansion protocol. Unlike the low-remaining amount of anti-viral TCRs throughout the expansion, the quantity of the RCC-associated TCRs was high in the tumors and pre-REP TILs but decreased in the REP TILs. Our results provide an in-depth understanding of the origin, phenotype, and TCR specificity of RCC TIL products, paving the way for a more rationalized production of TILs. SIGNIFICANCE: TILs are a heterogenous group of immune cells that recognize and attack the tumor, thus are utilized in various clinical trials. In our study, we explored the TILs in patients with kidney cancer by expanding the TILs using a clinical-grade protocol, as well as observed their characteristics and ability to recognize the tumor using in-depth experimental and computational tools.
MEMBER ACCOUNT
登录成功会直接打开下一页。